Tert-butyl n-[(3-aminophenyl)methyl]-n-methylcarbamate, 97%, 1g

Tetrahydrofuran-2-carboxylic acid, 95.0%, 500g

2,5-Bis(4-bromophenyl)-1,1-dimethyl-3,4-diphenylsilole>95.0%(GC)1g

(3-Bromopyridin-4-yl)carbamic acid tert-butyl ester, 95.0%, 5g

Oxalic acid diethyl ester, >=99%, for synthesis, 250 ml, plastic packaging.

(S)-3-(4-Fluoro-benzenesulfonyl)-pyrrolidine-1-carboxylic acid tert-butyl ester, 95.0%, 500mg

[(2R,3S,4R,5R)-5-(4-Benzamido-2-oxo-1,2-dihydropyrimidin-1-yl)-3-(benzoyloxy)-4-fluoro-4-methyloxolan-2-yl]methyl benzoate, 98%, 250mg

(R)-N-Methyl-1-phenylethanamine, 95.0%, 250mg

Boc-Hyp-OH, 98.00%, 10g

Benzo-2,1,3-thiadiazole-5-carboxylic acid, 95.0%, 1g

Na-Boc-Ne-Azido-L-Lysine cyclohexylammonium salt, 99.0%, 1g

Fmoc-3-amino-4-methoxy-benzoic acid, 99.0%, 1g

Anti-Influenza A Virus Nucleoprotein Monoclonal Antibody (Preservative : 0.05% NaN3, Stabilizer : 1% BSA)0.2mL